0 11

Cited 0 times in

Efficacy and safety of CKD-11101 (darbepoetin-alfa proposed biosimilar) compared with NESP in anaemic chronic kidney disease patients not on dialysis

Authors
Lee, JH; Ha Chung, B; Joo, KW; Shin, SK; Kim, YL; Na, KY; Do, JY; Park, SK; Shin, BC; Lee, JS; Kim, YW; Kim, SW; Lee, KW; Kang, GW; An, WS; Shin, GT; Han, S; Yang, CW
Citation
Current medical research and opinion, 35(6). : 1111-1118, 2019
Journal Title
Current medical research and opinion
ISSN
0300-79951473-4877
Abstract
OBJECTIVE: To evaluate the efficacy and safety of CKD-11101 (biosimilar darbepoetin-alfa, Chong Kun Dang Pharm.) compared with NESP(R) in treatment of anaemia in patients with chronic kidney disease not on dialysis.
CLINICAL TRIAL REGISTRATION: NCT03431623.
METHOD: In this multi-centre, randomized, double-blind study, patients were treated with CKD-11101 and NESP. The efficacy evaluation period (EEP) was 24 weeks, during which patients were treated every 2 weeks. All patients who completed the EEP were treated with CKD-11101 every 2 weeks for the first 4 weeks and every 4 weeks for the safety evaluation period (SEP), which was from 24 weeks to 52 weeks. The primary efficacy endpoint was the change in mean haemoglobin (Hb) level from baseline to end of EEP and mean dose needed to achieve the target Hb.
RESULTS: The mean Hb level was increased in both groups during the EEP (both p < 0.001). The difference in mean Hb level change between the two groups was 0.01 g/dL (95% CI = -0.213-0.242), indicating that CKD-11101 was equivalent to NESP. The difference in mean administration dose between groups was -1.40 mcg (95% CI = -6.859-4.059) included in the equivalent range. The incidence of AEs and ADRs was not different between the two groups, and the frequency of ADRs was favourable in both groups (1.2% in CKD-11101 vs 7.7% in the NESP to CKD-11101 conversion group).
CONCLUSION: CKD-11101 has an equivalent therapeutic effect as NESP in chronic kidney disease patients with renal anaemia. CKD-11101 can be safely used for long-term treatment and in patients converted from NESP.
Keywords
AnaemiaChronic kidney diseaseDarbepoetinErythropoiesis stimulating agentErythropoietin
MeSH terms
AdultAgedAnemia / drug therapy*Biosimilar Pharmaceuticals / adverse effectsBiosimilar Pharmaceuticals / therapeutic use*Darbepoetin alfa / adverse effectsDarbepoetin alfa / therapeutic use*Double-Blind MethodFemaleHumansMaleMiddle AgedRenal Dialysis* / adverse effectsRenal Insufficiency, Chronic / complications*Renal Insufficiency, Chronic / therapy
DOI
10.1080/03007995.2018.1560134
PMID
30569763
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Nephrology
AJOU Authors
신, 규태
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse